Y Intercept Hong Kong Ltd Makes New $64,000 Investment in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Y Intercept Hong Kong Ltd bought a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 43,940 shares of the company’s stock, valued at approximately $64,000.

Other hedge funds have also made changes to their positions in the company. Moloney Securities Asset Management LLC purchased a new stake in shares of Allogene Therapeutics in the 1st quarter worth about $431,000. Exchange Traded Concepts LLC lifted its holdings in shares of Allogene Therapeutics by 13.5% in the first quarter. Exchange Traded Concepts LLC now owns 68,858 shares of the company’s stock valued at $101,000 after purchasing an additional 8,183 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Allogene Therapeutics in the first quarter valued at about $28,000. California State Teachers Retirement System grew its position in shares of Allogene Therapeutics by 6.0% in the fourth quarter. California State Teachers Retirement System now owns 135,554 shares of the company’s stock valued at $289,000 after purchasing an additional 7,685 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Allogene Therapeutics by 18.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 270,559 shares of the company’s stock worth $576,000 after purchasing an additional 41,753 shares in the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Price Performance

Shares of ALLO stock opened at $1.23 on Friday. Allogene Therapeutics, Inc. has a 1-year low of $0.86 and a 1-year high of $3.78. The firm’s 50-day simple moving average is $1.28 and its 200-day simple moving average is $1.52. The firm has a market cap of $269.04 million, a P/E ratio of -1.00 and a beta of 0.31.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.28). Analysts expect that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Citizens Jmp lowered Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 14th. Truist Financial reduced their price objective on Allogene Therapeutics from $14.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Citigroup decreased their price objective on Allogene Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, May 15th. Royal Bank Of Canada reiterated an “outperform” rating and set a $10.00 price objective on shares of Allogene Therapeutics in a research report on Wednesday, May 14th. Finally, Piper Sandler decreased their price target on shares of Allogene Therapeutics from $9.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.44.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).